Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript

Neal Walker: Gavin. It’s a good question because, I think on the face, you look at it and say, well, it’s a black box. And then, I mean, I could tell you having practiced, oftentimes, it’s more of a chore for the physician to explain the laundry list of things that could happen. However, I would say that in talking to various colleagues over the last couple of years, I really don’t think and I think this is reflected in their sales. I really don’t think it’s been that big of a hindrance once you explain the issues. And at the end of the day, patients want their disease to be better. And we know that there really hasn’t been much tail off at all. In fact, baricitinib has been growing in alopecia areata. You’ve seen nice growth with RINVOQ and atopic dermatitis.

And there’s a reason. It provides order of magnitude benefit over biologics for sure. So I think at the end of the day, when patients want relief and they know they’re going to get it very quickly rather than perhaps waiting 16 weeks for a biologic to kind of take get to max effect, that’s important.

Operator: I’m showing no further questions at this time. I would now like to turn the conference back to Neal Walker for closing remarks.

Neal Walker: Well, thanks everybody for joining our call today. We’re excited to provide additional updates in the coming months and appreciate your time. Thank you.

Operator: This concludes today’s conference call. Thank you for participating and you may now disconnect.